Compare Rigetti Computing Inc (RGTI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs ResMed Inc. — how do they compare? Rigetti Computing Inc trades at $14.03 (market cap $4.72B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 6.8× Rigetti Computing Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rigetti Computing Inc for 35 Days and ResMed Inc. for 51 Days on average.
| RGTI | RMD | |
|---|---|---|
Market Cap | $4.72B | $31.89B |
Volume | 17,136,381 | 618,314 |
Sector | Technology | Health |
52-Week High | $56.34 | $277.88 |
52-Week Low | $12.90 | $182.82 |
Typical Hold Time | 35 Days | 51 Days |
Enterprise Value | $4.33B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGTI trades at $14.14, down 3.08% today, amid bearish technical signals despite bullish oscillators. The company shows negative profitability with a -1,787.4% net income margin and -$216.21M net loss for 2025, though revenue grew to $13M in 2026. Recent news highlights Rigetti's hybrid quantum-HPC strategy advancements and sector momentum from IonQ's developments.
Wall Street maintains strong bullish sentiment with 6 buy ratings and a $21.67 price target, representing 53% upside. However, significant execution risks persist given negative cash flow, high valuation multiples, and intense quantum computing competition. The stock offers high-risk growth potential for investors comfortable with speculative emerging technology plays.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
